A carregar...

Optimizing therapy for mantle cell lymphoma

Most people with mantle cell lymphoma (MCL) present with diffuse adenopathy and benefit from early initiation of rituximab and high-dose cytarabine- or bendamustine-based therapies. Some patients, however, present with primarily nonnodal disease that can follow either an indolent or a rapidly progre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hematology Am Soc Hematol Educ Program
Autor principal: Martin, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6142585/
https://ncbi.nlm.nih.gov/pubmed/29222271
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!